M&A Healthcare Advisors (“MAHA”) is pleased to present Project Revival (the “Company”), a pioneering regenerative medicine hub with a proven track record in cutting-edge therapies and patient-focused care.
Founded in 2018, the Company has grown into a premier destination for regenerative medicine in its market, offering a broad range of services including stem cell therapy, platelet-rich plasma (PRP) therapy, exosome therapy, and IV nutrition. The practice serves a diverse patient base seeking advanced solutions for orthopedic, anti-aging, sexual wellness, and chronic condition needs.
With a team of experienced providers, the Company delivers high-quality, outcomes-driven treatments supported by best-in-class protocols. Its reputation for innovation, patient satisfaction, and strong clinical results has led to sustained growth and expanding referral relationships.
The business operates from a state-of-the-art facility and is positioned for scalable expansion through additional locations, strategic partnerships, and enhanced marketing initiatives. All employees are expected to remain post-transaction, ensuring continuity for both patients and operations.
2023 | 2024 | TTM (Sep 2025) | 2025 YTD Jan-Sep (9mos) | |
|---|---|---|---|---|
Revenue | 944k | 709k | 889k | 763k |
EBITDA | 108k | 94k | 120k | 146k |
EBITDA Margin | 11% | 13% | 13% | 19% |
The owners have retained MAHA to explore a sale of the business. They are seeking a buyer who can continue to scale the model regionally and nationally while maintaining the Company’s reputation for quality and patient-centered care.
